Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer

Ann Oncol. 2015 Dec;26(12):2503. doi: 10.1093/annonc/mdv385. Epub 2015 Sep 14.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Cetuximab / administration & dosage*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics*
  • Disease-Free Survival
  • Humans
  • Mutation / genetics*
  • Prospective Studies
  • Proto-Oncogene Proteins p21(ras) / genetics*

Substances

  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
  • Cetuximab